Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jan 07, 2023 11:19am
243 Views
Post# 35208688

RE:RE:ONCY's pelareorep activates interferon (IFN) signalling

RE:RE:ONCY's pelareorep activates interferon (IFN) signallingIn an earlier post I explained how ONCY's oncolytic virus pelareorep down-regulates HIF-1a by an activated IFN-gamma, which in turn down-regulates adenosine, a downstream chemokine-like catalyst in the TME hypoxia pathway, that acts as a potent TME immunosuppressive agent.

As further background, in 2019 the Nobel Prize in Physiology or Medicine was awarded to William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza for their discovery of hypoxia-inducible factor (HIF), a key transcription factor that regulates gene expression in response to decreases in cellular oxygenation.

ONCY's pelareorep MOA in remodeling an immunosuppressive TME in advance of the sequential  addition of a checkpoint inhibitor is supported by Gregg Semenza's work that awarded him the 2019 Nobel Prize in Physiology and Medicine.
<< Previous
Bullboard Posts
Next >>